@article{PCM4680,
author = {Paul Hofman},
title = {Radiomic features of the lung: a promising marker to predict response to immune-checkpoint inhibitors in non-small lung cancer patients},
journal = {Precision Cancer Medicine},
volume = {2},
number = {0},
year = {2019},
keywords = {},
abstract = {First- or second-line immunotherapy administered to patients with advanced stage or metastatic (stage IIIB/IV) lung cancer give spectacular results in terms of overall survival but only for a limited number of patients. The objective now is to increase the percentage of patients who benefit from effective treatment but also to better select the patients receiving therapy and to propose, if required and without delay, an alternative therapy. It is within this context that biomarkers predictive of the response to immune-checkpoint inhibitors have been developed and then validated during clinical trials.},
issn = {2617-2216}, url = {https://pcm.amegroups.org/article/view/4680}
}